Pam Diamond spent almost three decades practicing medicine and looking at problems in the clinical research arena before changing tack so she could make a bigger impact.
Pfizer has been accused of ‘bringing discredit’ on the pharma industry after senior employees promoted its ‘unlicensed’ COVID-19 vaccine through social media at the height of the pandemic.
The FDA has agreed to permanently remove several social media posts urging people not to take ivermectin for the treatment of COVID-19, after a lawsuit brought by three doctors accused the regulatory body of interfering with their ability to practice...
AstraZeneca CEO Sir Pascal Soriot has been awarded one of the highest honours by science institution SCI for his role in ‘accelerating scientific innovation’ and for leading the company’s global COVID-19 vaccination programme.
AstraZeneca recently announced its £650 million investment in the UK, held up by Chancellor Jeremy Hunt as a ‘vote of confidence’ in the country’s life sciences sector.
Kate Broderick takes us on her intriguing journey - from being drawn to how science was applied within a medical setting, to the enormous challenge of working around the clock when the pandemic began.
One of the most challenging aspects of the COVID-19 pandemic was not being able to assess how individual patients would respond to the virus and how severe their symptoms would be.
Despite previously calling the UK a ‘very unattractive’ place to do business, AstraZeneca CEO Pascal Soriot is injecting £650 million into the UK life sciences industry.
PrecisionLife has partnered with healthcare center the Metrodora Institute to jumpstart the diagnosis and treatment options for a range of chronic diseases including long COVID, ME/CFS, ALS and Sjögren's syndrome.
Japanese pharmaceutical company Shionogi has announced the first peer-reviewed publication of its phase 3 study investigating ensitrelvir to treat patients with mild to moderate COVID-19 in Japan, South Korea and Vietnam.
Large-scale global serologic surveillance with real-time monitoring of the immune status of human populations and detection of viral outbreaks could be enabled by new technology from Picodya.
Moderna has revealed that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Spikevax, its updated COVID-19 vaccine.
BioNTech and Pfizer have received a positive opinion from The Committee for Medicinal Products for Human Use (CHMP) for their updated COVID-19 vaccine, as a single dose for individuals 5 years of age and older, regardless of prior vaccination history,...
LinKinVax, a clinical-stage biotech company, has announced the manufacture and bottling of a GMP batch of its next generation pan-sarbecovirus vaccines, known as PanCov, designed to prevent COVID-19 and other known coronavirus diseases.
PrecisionLife, a computational biology company driving precision medicine in complex chronic diseases, has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other...
Shionogi has enrolled the first participant in Japan in its phase 3 clinical trial of oral antiviral ensitrelvir to stop the post-infection progression of Covid-19.
InflaRx’s Gohibic (vilobelimab), a monoclonal anti-human complement factor C5a antibody, has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adults.
The messenger RNA (mRNA) specialist Moderna has teamed up with ElevateBio-owned Life Edit Therapeutics to develop gene editing therapies that are delivered into patients in vivo.
Daiichi Sankyo is kitting out a plant, based near Tokyo in Kitamoto, with equipment to enable the production of an mRNA vaccine against COVID-19, according to a Nikkei Asia report.
US contract development and manufacturing organization, Catalent, reported results today for the second quarter of fiscal 2023, which ended December 31, 2022.
While the pandemic brought new entrants into the market, vaccine manufacturing remains a complex activity undertaken by a limited number of companies with the overall picture largely unchanged by COVID-19.
Vaxxas has completed a financing round which raised US$23m (A$34m) in new funds: allowing the company to progress multiple vaccine programs in the clinic and ramp up manufacturing capabilities towards commercial scale.
GeNeuro has recruited the first patients in a Phase 2 trial evaluating temelimab against long-COVID: assessing the efficacy of the treatment for improving cognitive impairment and fatigue.
BioNTech is set to take several mRNA candidates into clinical trials over the coming months: including vaccines for shingles, malaria and tuberculosis.
The model for COVID-19 vaccines will undoubtedly change next year: but what this will look like in terms of key metrics such as number of doses and revenues remains in question.
CSL Limited has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings to access its late stage, next-generation self-amplifying mRNA (sa-mRNA) vaccine tech: prepared to spend more than $4bn on the deal to accelerate its...
Shares of Catalent Inc plunged yesterday after the contract development and manufacturing organization (CDMO) reported fiscal first-quarter profit and revenue that missed expectations. The company also scaled back its full-year outlook.
Addition, Talis Capital, and Speedinvest were among the investors participating in the round. Seqera Labs had previously secured €4.4m (US$4.3m) in seed funding, plus grants from the Chan Zuckerberg Initiative.
As the US government stops buying COVID-19 shots, Pfizer said the vaccine it developed with BioNTech will be sold for US$110 to US$130 per dose, from as early as the first quarter 2023.
The US regulator has given the green light for the distribution of doses of Moderna's COVID-19 booster shots from a manufacturing plant in Indiana run by Catalent.
The EU’s tailor-made centralised system for vaccine procurement was successful in procuring sufficient doses of COVID-19 vaccines, but a new report finds holes in the approach.
Technology firm, Benchling, has developed what it calls the biopharma industry’s first set of full capabilities for designing, modelling, and studying both natural and chemically modified RNA in a single platform.
The US regulator has granted emergency authorization for Pfizer-BioNTech’s and Moderna’s Covid booster shots that target the highly contagious BA.5 omicron subvariant.
AstraZeneca's long-acting antibody combination Evusheld has been approved in Japan for both prevention (pre-exposure prophylaxis) and treatment of symptomatic disease caused by SARS-CoV-2 infection: marking the first global marketing approval of...
EMA has begun its review of the conditional marketing authorization application from South Korean developer, SK biosciences, for its COVID-19 vaccine, Skycovion, a recombinant protein-based vaccine with adjuvant from GSK.
GreenLight Biosciences and Samsung Biologics have completed the first commercial-scale engineering run under the companies’ mRNA production partnership: ahead of a COVID-19 vaccine booster clinical trial due to start later this year.
A representative from life-science services company Azzur Group explains how flexibility and speed can help in reaching the best solution more efficiently.
